Brief: Matinas Biopharma Holdings Reports Q3 Loss Per Share Of $0.03
13/11/2019 12:17
Nov 13 (Reuters) - Matinas BioPharma Holdings Inc MTNB.A :
* MATINAS BIOPHARMA REPORTS THIRD QUARTER 2019 FINANCIAL
RESULTS
AND PROVIDES CORPORATE UPDATE
* Q3 LOSS PER SHARE $0.03
* Q3 EARNINGS PER SHARE ESTIMATE $-0.03 -- REFINITIV IBES
DATA
* CASH AND CASH EQUIVALENTS AT SEPTEMBER 30, 2019 WERE
APPROXIMATELY $32.7 MILLION
* INITIATED PRE-SCREENING OF PATIENTS FOR PHASE 2 ENHANCE-IT
STUDY
OF MAT9001 AGAINST VASCEPA
* BELIEVES THAT CASH ON HAND IS SUFFICIENT TO FUND
OPERATIONS INTO
Q1 OF 2021
* PHASE 2 ENHANCE-IT STUDY OF MAT9001 ENROLLMENT TO COMMENCE
Q1
2020, WITH TOPLINE DATA EXPECTED H2 2020
Source text for Eikon: ID:nGNXbKs3mH
Further company coverage: MTNB.A
(Reuters.Briefs@thomsonreuters.com)
Recent news on Matinas BioPharma Holdings
See all newsBrief: GH Power Signs Multi-Year Hydrogen Offtake Agreement With Change Energy For Hamilton Facility Output
Brief: Gh Power And Tkms Continue To Explore Clean Energy Collaboration In Support Of Canada’S Future Patrol Submarine Project
Brief: Matinas Biopharma - Btig Terminates Sales Agreement With Matinas Biopharma Holdings, Effective Immediately On July 23, 2026 - SEC Filing
Brief: Matinas Biopharma Receives Notice Of Non-Compliance With NYSE American Continued Listing Standards And Acceptance Of Plan To Regain Compliance
Brief: Matinas Biopharma - May Offer Securities Up To $150 Million - SEC Filing